COVID-19 大流行导致世界各地的卫生服务受到严重干扰。这项基于人群的研究的目的是评估大流行对前列腺癌 (PC) 相关诊断测试和治疗活动的下游影响。 2010 年 1 月至 2022 年 6 月期间查询了澳大利亚政府卫生部医疗保险福利计划和药品福利计划数据库。在新冠疫情之前（2010 年 1 月至 2020 年 2 月）和新冠疫情期间（2020 年 3 月至 2022 年 6 月）执行了两个中断时间序列）。进行时间建模以考虑季节变化。在 COVID-19 之前，每月前列腺特异性抗原 (PSA) 检测呈下降趋势，每年每 100 万人检测减少 81 次。 2020 年 4 月，PSA 检测单月下降 38%；这相当于澳大利亚的第一波浪潮。前列腺活检率没有观察到变化。在 COVID-19 爆发期间，有 4% 的人略微转向使用长效雄激素剥夺疗法 (ADT)，但仍偏爱短效药物。放射治疗或手术的总量没有变化。男性 PC 诊断和治疗活动的数量没有减少。除了在大流行期间稍微转向使用长效 ADT 外，没有观察到其他模式。由于 COVID-19 造成的漏诊或延迟就诊等影响生存机会的长期影响尚未确定。© 2023 作者。约翰·威利出版的《国际癌症杂志》

The COVID-19 pandemic led to a major disruption to health services across the world. The aim of this population-based study was to assess the downstream effects of the pandemic on diagnostic tests and treatment activities related to prostate cancer (PC). The Australian Government Department of Health Medicare Benefits Schedule and the Pharmaceutical Benefits Scheme databases were queried from January 2010 to June 2022. Two interrupted time series were performed Pre-COVID (January 2010 to February 2020) and peri-COVID (March 2020 to June 2022). Temporal modeling was performed to account for seasonal variation. Pre-COVID-19, monthly prostate-specific antigen (PSA) testing showed a declining trend and testing decreased by 81 tests per 100 000 annually. A single-month 38% drop in PSA testing was observed in April 2020; this corresponded to Australia's first wave. No change was observed in the rate of prostate biopsies. Peri-COVID-19 outbreaks, there was a slight shift toward the use of long-acting androgen deprivation therapy (ADT) at 4% with a predilection still for short-acting agents. with no registered change in the overall volume of radiotherapy or surgery. There were no deficits in the number of diagnostic and treatment activities for men with PC. Aside from a slight shift toward long-acting ADT use during the pandemic, no other patterns were observed. The longer-term impact such as missed diagnosis or late presentation affecting chances of survival due to COVID-19 is yet to be ascertained.© 2023 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.